|
|
LETTER TO EDITOR |
|
|
|
Year : 2011 | Volume
: 43
| Issue : 1 | Page : 95 |
|
Authors' reply
Harminder Singh, Navin Dulhani, Bithika Nel Kumar, Prabhakar Singh, Pawan Tiwari
Department of Pharmacology, Government Medical College, Jagdalpur, Chhattisgarh, India
Date of Web Publication | 15-Jan-2011 |
Correspondence Address: Harminder Singh Department of Pharmacology, Government Medical College, Jagdalpur (C.G) - 494 001, Chhattisgarh India
 Source of Support: None, Conflict of Interest: None  | Check |
PMID: 21455442 
How to cite this article: Singh H, Dulhani N, Kumar BN, Singh P, Tiwari P. Authors' reply. Indian J Pharmacol 2011;43:95 |
Sir,
This is with reference to the comments on our article. [1],[2] Respected reader has raised his/her concern on the criteria that merited its publication. In support of our published article, we humbly put forward the following:
- The established drug efficacy studies/concepts need repetition in different gene pool/geographical area to verify the optimal results in diverse situations. [3],[4] The repeated validation in dissimilar condition makes the established fact more relevant.
- Apart from the efficacy of hydroxyurea, we also had our concern about safety aspects throughout the study period. [2]
- Even the negative results are welcome in scientific community and some of the journals are fanatical for this job. We have conducted a scientifically sound, ethically approved, prospective study in sickle cell disease endemic tribal area which itself holds some logical merit to make a place in indexed journal. [5]
- Our main objective was to recommend a wider adoption of hydroxyurea for treatment in areas of high prevalence of sickle cell disease, which is still lacking. The Indian Journal of Pharmacology has shown a full accountability and scientific conclusion to decide on this study in their much valued journal.
» References | |  |
1. | Beedimani R. The novelty of research article: Whose responsibility is it? Indian J Pharmacol 2011;43:94-5.  |
2. | Singh H, Dulhani N, Kumar BN, Singh P, Tiwari P. Effective control of sickle cell disease with hydroxyurea therapy. Indian J Pharmacol 2010;42:32-5.  [PUBMED] |
3. | Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1.  |
4. | Jayabose S, Tugal O, Sandoval C, Patel P, Puder D, Lin T, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:559-65.  [PUBMED] [FULLTEXT] |
5. | A biannual newsletter of regional medical research centre for tribals, Jabalpur, April 2005. Available from: http://www.icmr.nic.in/000519/Newsletter_vol2No1.pdf. [last accessed on 2009].  |
|